.
MergerLinks Header Logo

Announced

Completed

CR-CP Life Sciences led a $77m Series C funding round in MiRXES from CDG Capital and NHH Ventures.

Financials

Transaction Value

£62m

Consideration Type

Cash

Capital Owned

+ Add

Capital bid for

+ Add

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

+ Add

Transaction Tags

cancer detection diagnostics

Private

Minority

Completed

Acquisition

Singapore

Cross Border

Single Bidder

Friendly

Health Care Services

Private Equity

Synopsis

CR-CP Life Sciences, a private equity firm, led a $77m Series C funding round in MiRXES, a Singapore-based early cancer detection diagnostics company, from CDG Capital and NHH Ventures. “We are pleased to welcome Mr. Liu to MiRXES’s Board of Directors as we continue on our exciting journey in delivering early, actionable and personalized diagnoses across the care continuum to save and improve lives. MiRXES is a global organization and Mr. Liu brings international business perspective and leadership to our efforts in creating breakthroughs and expanding MiRXES’s footprint across the globe in cancer early detection and precision medicine,” Dr. Lihan ZHOU, MiRXES Co-Founder and CEO.

Sources

Press Release

MiRXES

Financials

Transaction Value

£62m

Consideration Type

Cash

Capital Owned

+ Add

Capital bid for

+ Add

EV/Sales

+ Add

EV/EBITDA

+ Add

Share Price Premium

+ Add

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US